Email
Print
Pancreatic Fistula Market Overview
The Pancreatic Fistula Market Size is estimated to reach $1.8 billion by 2027 and is poised to grow at an estimated CAGR of 5.8% over the forecast period of 2022-2027. Pancreatic fistula is an improper connection between the pancreatic ductal epithelium and another epithelial surface. This is carried on by an obstruction in the pancreatic ducts that causes the fluid produced by the pancreas to leak, causing erosion and the formation of various paths that result in internal and exterior pancreatic fistulas associated with the esophagus. If the leakage exceeds a particular point and is not treated effectively, it results in infection, excoriation or, in the worst cases, morbidity from malnutrition. There are three different forms of pancreatic fistulas, including high output, mixed and end fistulas. When a fistula is high, it can produce more than 200 mL of fluid in a day, drain pancreatic fluid together with enteric contents and eventually cause a fistula’s pancreatic ducts to become disfigured. Pancreaticopleural fistulae are however more unusual than pancreatic ascites. It usually presents as a large recurrent pleural effusion in either pleural space, but left-sided effusion is more common and is reported to account for 76% of cases.
For treatment of external and internal fistula, various therapeutic options are considered such as percutaneous, medical, surgical and endoscopic. Endoscopic retrograde cholangiopancreatography (ERCP) and contrast-enhanced computed tomography are required for the diagnosis of pancreatic fistula (CECT) and medication such as somatostatin analogs are used as a treatment for pancreatic fistula. Between 13 to 41% of patients get postoperative pancreatic fistula (POPF), which continues to be the predominant cause of substantial morbidity and mortality following pancreatic resection. Such a growing risk of Pancreatic Fistula drives the growth of the Pancreatic Fistula Industry over the forecast period 2022-2027.
Pancreatic Fistula Market Report Coverage
The “Pancreatic Fistula Market Forecast (2022-2027)" by IndustryARC, covers an in-depth analysis of the following segments in the Pancreatic Fistula Market.
by Treatment: Drugs [octreotide and total parenteral nutrition (TPN)] and Surgical Device.
by Application: Hospitals, Clinics, Ambulatory Surgical Centers and Others.
by Geography: North America (the U.S., Canada and Mexico), Europe (Germany, the U.K., France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia and New Zealand and the Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021. The growing cases of postoperative pancreatic fistula associated with the esophagus and better healthcare facilities available to treat such diseases are driving the growth of the Pancreatic Fistula Market size in this region.
- The Pancreatic Fistula Market is predicted to grow because of the increase in the number of people who consume alcohol.
- However, the chances of complications after surgery may hamper the market growth.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Pancreatic Fistula Market Report.
Pancreatic Fistula Market: Market Share (%) by region, 2021.
Pancreatic Fistula Market Segment Analysis- by Treatment
The Pancreatic Fistula Market based on treatment can be further segmented into Drugs and Surgical Devices. The Drugs segment held a dominant market share in the year 2021. The preoperative medication can reduce the chances of post-operative pancreatic fistula associated with the esophagus. From a research study published in Science Direct, it is proved that the use of somatostatin analogs, has the potential to reduce post-operative pancreatic fistula. According to a research article published in PLOS ONE in June 2021, 45% of postoperative pancreatic fistula associated with the esophagus result in morbidity. The Lanreotide Prefilled Syringe developed by the University of Washington was in phase II trial in June 2022. The Lanreotide Prefilled Syringe was designed to test the feasibility and potential efficacy of preoperative lanreotide to reduce the risk of postoperative abscess or pancreatic leak and fistula. Such innovations and the use of proper medication such as somatostatin analogs minimize the incidence of postoperative Pancreatic Fistula and drive the growth of the Pancreatic Fistula Market Share.
However, Surgical Device is estimated to grow with the fastest CAGR of 6.4% over the forecast period 2022-2027. This is owing to the use of sphincterotome, biliary & pancreatic stents, guidewires, balloons and cannulae during pancreatic surgery. The high cases of pancreatic fistula associated with the esophagus surge demand for such medical equipment which propels the growth of the Pancreatic Fistula Market. In 2020, about 394 pancreatic resections were performed in The Pancreas Institute of the University of Verona, Italy. Such growing cases of pancreatic resection as a result of disruption of pancreatic duct surge demand for pancreatic surgery and drive the growth of the Pancreatic Fistula Market Share over the forecast period 2022-2027.
Pancreatic Fistula Market Segment Analysis - by Application
The Pancreatic Fistula Market based on the application can be further segmented into Hospitals, Clinics, Ambulatory Surgical Centers and others. The hospital segment held a dominant market share in the year 2021. This is owing to the growing number of super specialty hospital chains and the presence of key market players across the globe. According to ‘Hospital Management.net’ the United States, India and China ranked in the top position with new hospital projects completed in 2022 and the number of new beds per 100,000 population. Such a growing strength of the healthcare system and the availability of specialty hospitals drive the growth of the Pancreatic Fistula Market Share.
However, Ambulatory Surgical Centers are estimated to grow with the fastest CAGR of 6.7% over the forecast period 2022-2027. This is owing to attributes of ambulatory surgical centers which provide same-day diagnosis, treatment and care popularised ambulatory surgical centers. Also, growing development in ambulatory surgical centers such as acquisition, joint ventures, mergers and others drive the growth of the ambulatory surgical centers. For instance, in December 2021, Tenet and its subsidiary USPI completed a $1.1 billion acquisition of SurgCenter Development, which expanded its portfolio and added up 86 more ambulatory surgery units and related support services. Such a growing expansion of ambulatory surgical centers and increasing preference for ambulatory surgical centers fuel the growth of the Pancreatic Fistula Market Share over the forecast period 2022-2027.
Pancreatic Fistula Market Segment Analysis - by Geography
The Pancreatic Fistula Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant market share of 35% in the year 2021. This is the result of the best health care facilities available in this region and the strong presence of key market players. Also, an increase in alcohol consumption among the population increases the risk of disruption of pancreatic ducts and enhances the probability of pancreatic fistula associated with the esophagus. According to the National Institute of Alcohol Abuse and Alcoholism, 85.6% of people ages 18 and older reported that they drank alcohol at some point in their lifetime. In 2019, 25.8% of people aged 18 and older reported that they engaged in binge drinking and 6.3% reported that they engaged in heavy alcohol use. Such a growing percentage of alcohol drinking in this region put people at high risk of Pancreatic Fistula and drives the growth of the Pancreatic Fistula Market.
Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is owing to the growing geriatric population which is susceptible to pancreatic cancer, adenocarcinoma, pancreatic neuroendocrine tumors and other gastrointestinal and lifestyle diseases. According to a research paper published in National Center for Biotechnology Information (NCBI) in July 2021, pancreatic cancer incidence is raised by 46% in Asia and Australia in 2019. Also, the growing investment in healthcare infrastructure and effective methods to treat & diagnose Pancreatic Fistula propel the growth of the Pancreatic Fistula Market size in the Asia-Pacific region over the forecast period 2022-2027.
Pancreatic Fistula Market Drivers:
Increasing Geriatric Population with Risk of Pancreatic Duct Disruption:
Elder people are more prone to diseases and the risk of disruption of the pancreatic duct, pancreatic cancer or Pancreatic Fistula is high in the elderly population. According to cancer.net, all ages have an incidence rate of 11.7% for pancreatic cancer, but those over 65 and over 80 had an incidence rate of 66.4% and up to 91.1%, respectively. With a growing percentage of the elderly population, the risk of the pancreatic fistula is also increased. Globally, it is anticipated that the percentage of people 65 and older would rise from 9.3% in 2020 to about 16% in 2050, as per the United Nations Department of Economics and Social Affairs. Such a high growth of the elderly population and increased risk of Pancreatic Fistula drive the growth of the Pancreatic Fistula industry over the forecast period 2022-2027.
Growing Consumption of Alcohol:
The consumption of alcohol increases the chances of pancreatic cancer & Pancreatic Fistula and also leads to disruption of pancreatic ducts. According to American Addiction Center Organization, heavy consumption of alcohol increases the risk of pancreatitis. It disrupts the mechanism of enzymes produced by the pancreas. The pancreas can activate enzymes that ordinarily discharge into the digestive tract and activate when they reach the small intestine. As a result, the pancreas starts to "digest" itself. As per a research paper published by the National Center for Biotechnology Information (NCBI) in June 2020, drinking 30 grams or more of alcohol per day or more was associated with a slight increase in the risk of pancreatic cancer, according to a pooled analysis of 14 cohort studies. According to another research study published in the European Journal of Cancer in March 2022, 9,514,171 adults without cancer underwent health examinations under the Korean National Health Insurance Service in 2009 and were followed up until December 2022 for pancreatic cancer development. In patients with impaired fasting glucose (IFG), pancreatic cancer risk grew with increased frequency and average daily amount of alcohol consumption. Such a relation between the consumption of alcohol and the risk of pancreatic cancer drives the growth of the Pancreatic Cancer Industry over the forecast period 2022-2027.
Pancreatic Fistula Market Challenge:
High Price of Treatment:
The approximate cost of pancreatic cancer treatment in India is between 532,499.12 INR to 745,529.31 INR, as per MedSurgeIndia, the most reputable company in the field of medical tourism in India. Such high-cost of treatment for pancreatic cancer treatment is out of pocket for low and middle-income groups. According to data from the Reserve Bank of India and Census of India, the per capita healthcare spending was 1,584 INR in 2021-2022. Such low per capita healthcare spending and the high price of treatment hinder the growth of the Pancreatic Fistula Industry.
Pancreatic Fistula Industry Outlook:
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Pancreatic Fistula Market. The top 10 companies in the Pancreatic Fistula Market are:
- Cook Medical, Inc.
- CONMED Corporation
- Fresenius Kabi AG
- B. Braun Melsungen Ag
- Becton Dickinson & Company
- Baxter International, Inc.
- Ethicon USA, LLC
- Medtronic plc
- Novartis AG
- Olympus Corporation
Recent Developments
- In May 2022, CONMED Corporation announced a definitive agreement to acquire privately-held In2Bones Global, Inc. for cash consideration of $145 million at closing and up to an additional $110 million in growth-based earnout payments over a four-year period. In2Bones is a global developer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities.
- In March 2022, Fresenius Kabi AG announced the acquisition of a 55% stake in mAbxience Holding S.L. The purchase price would be a combination of €495 million upfront payment and milestone payments. mAbxience is a leading international biopharmaceutical company, focused on the rapidly developing biosimilars market.
- In February 2022, Cook Medical, Inc signed a letter of intent with Cooper Companies to sell the entirety of Cook’s Reproductive Health business within the MedSurg division. Cooper Companies, a publicly held healthcare company, is focused on women’s health and fertility solutions and provides innovative products and services.
Relevant Titles
Intraoperative Imaging Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0444
Report Code: HCR 0694
Report Code: HCR 0114
For more Lifesciences and Healthcare Market reports, please click here